Britain and America have established a landmark bilateral deal that will ensure no duties on UK medicine products being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on pharmaceuticals through the National Health Service (NHS). This commitment ensures that import taxes on these crucial products will be held at zero for a timeframe of the next three years.
This development comes after earlier threats to hike import taxes on patented drug imports, with increases discussed reaching one hundred percent.
"This agreement with the Britain strengthens the global environment for cutting-edge drugs and introduces long-overdue balance to transatlantic pharmaceutical trade," an announcement noted.
Economic Impact
Medicines constitute one of the UK's biggest export categories to the US, which is easily the primary market for large UK drugmakers.
Export figures show that in the one-year period to the end of last September, the UK exported medicines totaling £11.1bn to the US. This figure accounted for nearly one-fifth of British export trade in that period.
"This guarantee safeguards employment, boosts capital expenditure and sets the stage for the UK to emerge as a global hub for life sciences," a minister commented.
Key UK Commitments
The agreement includes several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it considers new treatments to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a target to double overall health service expenditure on treatments from 0.3% of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The sum pharmaceutical firms must refund to the NHS to prevent overspending will be capped at fifteen percent. In the past, repayments were more than 20%.
Industry Background
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by arguments that US patients were charged significantly more for the identical medicines than consumers in the UK and Europe.
In recent months, several major drug company projects in the UK have been delayed or abandoned, while major investments have been pledged toward US facilities.
One official publicly accepted that the NHS must invest a greater share on treatments, noting that its spending on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
